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Abstract
I In nt tr ro od du uc ct ti io on n: : The “a distintegrin and metalloprotease” (ADAM) family contributes
to regulation of the cell-cell and cell-matrix interaction that are critical deter-
minants of malignancy. It also plays important roles in the degradation of the
basement membrane during tumor invasion. To evaluate a distinguishing bio-
marker for hepatocellular carcinoma from cholangiocarcinoma, a disintegrin and
metalloprotease 12 (ADAM12) level was determined.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   The indirect ELISA and Western blot analysis for quan-
tification of ADAM12 level in serum was developed. The subjects were 218 his-
tologically confirmed cases, 128 with intrahepatic cholangiocarcinoma, 30 with
hepatocellular carcinoma and 60 healthy people. 
R Re es su ul lt ts s: :   The ability of test was verified using an analysis of Receiver Operating
Characteristic (ROC) curve. The mean value of serum ADAM 12 in hepatocellu-
lar carcinoma was significantly higher than cholangiocarcinoma  and healthy
people (p = 0.001). The AUC for control vs. HCC was 0.826 while for controls vs.
CC was 0.679. The results showed that a disintegrin and metalloprotease 12 for
hepatocellular carcinoma had better specificity (77.4%) than for cholangiocar-
cinoma (64.5%). The serum a disintegrin and metalloprotease 12 level was also
found to inversely correlate with overall survival (p = 0.02).
C Co on nc cl lu us si io on ns s: :   A disintegrin and metalloprotease 12 would be most useful as an
adjunct biomarker for distinguishing hepatocellular carcinoma from cholangio-
carcinoma.
K Ke ey y   w wo or rd ds s: :   ADAM12 protein, cholangiocarcinoma, hepatocellular carcinoma, 
A disintegrin and metalloproteases.
Introduction
The two major subtypes of primary liver cancer are hepatocellular car-
cinoma (HCC) and cholangiocarcinoma (CC). Unlike HCC, CC contains a sig-
nificant amount of fibrous stroma and subsequently low incidence of metas-
tases of primary cancer. In fact, HCC patients have a similar clinical
presentation as CC, such as upper abdominal pain, dyspepsia and fatigue.
Therefore, initial misdiagnosis between HCC and intrahepatic or peripher-
al cholangiocarcinoma is commonly found, even though excellent studies
have revealed that the serum markers for HCC and CC screening diagnos-
tics are α-fetoprotein [1]  and MUC5AC [2], respectively. However, differen-
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tiation of HCC from CC by new serum markers is still
a challenging study. A disintegrin and metallopro-
teases (ADAMs) are membrane-anchored cell sur-
face glycoproteins. To date, more than 30 ADAMs
have been identified. ADAM12 belongs to the large
family of ADAMs and possesses extracellular met-
alloprotease and cell-binding functions, as well as
intracellular signalling capacities. Interest in ADAM12
has increased recently because its expression is
related to a variety of human cancers such as breast
[3], bladder [4], lung [5], and liver [6, 7]. ADAMs medi-
ated cancer cell proliferation and progression may
be connected with their structures, which have the
potential to possess protease, adhesion, fusion, and
signalling functions [8, 9]. Our report represents the
first study of the ADAM12 level in serum samples
taken from patients with chronic liver disease of dif-
ferent aetiologies. In this study, we developed an
enzyme-linked immunosorbent assay (ELISA) for the
quantification of ADAM12. 218 archived serum sam-
ples were tested.
Material and methods
P Pa at ti ie en nt ts s
Samples were obtained from patients with intra-
hepatic cholangiocarcinoma and hepatocellular car-
cinoma who had undergone surgery at Srinagarind
Hospital, Faculty of Medicine, Khon Kaen Universi-
ty, Khon Kaen, Thailand. Informed consent was
obtained from each patient. The Human Research
Ethics  Committee  of  Khon  Kaen  University
approved the protocol (HE500602). Preoperative
serum samples were obtained from 128 patients
with CC, and 30 with HCC. The group of healthy
adult controls consisted of 60 volunteers with the
same average age as the CC group. All serum sam-
ples were stored at –70°C until determined by ELISA
and Western blot analysis using specific antibody.
E En nz zy ym me e- -l li in nk ke ed d   i im mm mu un no os so or rb be en nt t   a as ss sa ay y   ( (E EL LI IS SA A) )   
Serum samples were prepared in triplicate at 
50 ﾵl/well, slightly modified from the previous report
[10]. Each well of the polystyrene microtitre plate
was coated with 1 ﾵg/50 ﾵl serum in 50 mM car-
bonate buffer, pH 9.5, and incubated overnight at
4°C. The wells were washed with Tris-buffered
saline (TBS, in mM: 10 Tris-HCl, pH 8.0 and 150 NaCl)
containing  0.05%  Tween  20  (TBST)  and  were
blocked with 5% skimmed milk in TBST for 60 min
at 37°C. After three washes, specific primary anti-
body (Rabbit anti-human ADAM12; Catalogue no.
A2601; Sigma), diluted in TBST, was incubated for
60 min at 37°C. The wells were washed with TBST
and incubated with secondary antibody (Goat anti-
rabbit Igs conjugated alkaline phosphatase) dilut-
ed in TBST. Following incubation at 37°C for 60 min,
the wells were washed with TBST and TBS and visu-
alized using freshly prepared chromogenic substrate
(1 mg/ml of p-nitrophenyl phosphate, 100 mM 
Tris-HCl, pH 9.5, 100 mM NaCl and 50 mM MgCl2).
The absorbance was measured at 405 nm (A405) by
an ELISA plate reader. 
W We es st te er rn n   b bl lo ot t   a an na al ly ys si is s
Equal amounts of proteins (20 mg) were sepa-
rated by 12% SDS-PAGE under reducing conditions.
Resolved proteins were electrophoretically trans-
ferred to nitrocellulose membranes. The mem-
branes were blocked and incubated with 1 mg/ml
of specific primary antibody (Rabbit anti-human
ADAM12; Catalogue no. A2601; Sigma). The sec-
ondary antibody (Goat anti-rabbit Igs conjugated
alkaline phosphatase) was subsequently incubat-
ed and then visualized using an Alkaline Phos-
phatase Conjugated Substrate Kit following the
manual protocol. Band intensities were analysed
with the ImageJ program.
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s
Mean levels of ADAM12 were compared between
cancers and control groups using one-way ANOVA.
The ability of serum ADAM12 to differentiate among
CC, HCC and control was utilized to plot all pairs of
true positives and false positives at various cut-off
levels.  To  evaluate  the  diagnostic  accuracy  of
ADAM12, receiver operating characteristic (ROC)
curve and the area under the curve (AUC) were
analysed. In addition, the survival curves were cal-
culated using Kaplan-Meier and log rank tests. The
result was considered statistically significant when
p < 0.05. All statistical analysis was performed using
SPSS (version 15.0).
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Results
S Se er ru um m   A AD DA AM M1 12 2   l le ev ve el l   
Serum level of ADAM12 is shown in Figure 1.
Mean levels in HCC (mean ± SD = 0.730 ±0.278, 
n = 30) were significantly higher (p < 0.001) than in
CC (mean ± SD = 0.313 ±0.130, n = 128) and healthy
controls (mean ± SD = 0.209 ±0.122, n = 60). We
also examined the serum ADAM12 by Western blot-
ting. The majority of samples from cancer patients,
especially in the HCC group, were strongly signifi-
cantly positive for ADAM12, in contrast to the nor-
mal serum samples (Figures 2 A and 2 B). The result
was similar to the ELISA, indicating that the devel-
oped technique is reliable. 
R Re ec ce ei iv ve er r   o op pe er ra at ti in ng g   c ch ha ar ra ac ct te er ri is st ti ic c   c cu ur rv ve es s
Based on the ROC curve analysis, the ADAM12
OD cut-off for control vs. HCC was 0.343 yield with
AUC = 0.826 while for controls vs. CC it was 0.265
yield with AUC = 0.679 (Figure 3). We also calcu-
lated the sensitivity, specificity, positive likelihood
ratio (PLR), and negative likelihood ratio (NLR) of
the marker. Our results showed that when com-
paring type of tumour, ADAM12 for HCC had better
specificity and PLR (77.4% and 3.51, respectively)
than for CC (64.5% and 1.25, respectively).
S Se er ru um m   A AD DA AM M1 12 2   a an nd d   s su ur rv vi iv va al l   r ra at te e
Cumulative survival was compared between 
60 patients with HCC. Serum ADAM12 in HCC was
significantly correlated with the overall survival 
(p = 0.02), indicating that a high serum level of
ADAM12 had a significantly poorer prognosis.
Discussion
As shown in Figure 1, the serum ADAM12 levels
were significantly higher in HCC than in CC. Simi-
larly, in vivo, Le Pabic et al. demonstrated that the
steady state of ADAM12 mRNA levels was nearly
undetectable in both normal livers and benign
tumours and increased in HCC up to 6-fold and in
liver metastases from colonic carcinomas up to 
60-fold [6]. Roy et al. demonstrated that ADAM12
cleaves various extracellular matrix protein mole-
cules  including  gelatin,  type  IV  collagen  and
fibronectin, suggesting that the role of ADAM12 in
cancer development and metastasis may be linked
to their proteinase activity [3]. Schwettmann et al.
suggested that ADAMs are differentially expressed
in the liver. They assumed that ADAM-9, -TS1 23 and
-TS2 play a crucial role in ECM remodelling during
fibrotic processes in the liver [7] with the same as
MMP2 and MMP9 in other chronic disease [11].
Based on tumour cell behaviour, there is mostly no
distant metastasis and regional lymph node metas-
tasis is common in CC while vascular invasion is less
than in HCC. In this study, ADAM12 can discriminate
CC patients from those with HCC who have similar
clinical presentations. Thus, serum ADAM12 would
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F Fi ig gu ur re e   2 2. .   Western blot analysis of serum protein. 
A A – Representative serum samples (20 mg of total
protein per sample) from controls, CC and HCC were
probed with ADAM12-specific. The bands of serum
controls (lanes 2-4), CC (lanes 5-7) and HCC (lanes
8-12) are shown. B B – Histogram of densitometry of
the immunoblots indicates the increase in mean lev-
els of serum ADAM12 with diseases status. The error
bars denote standard errors
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be most useful as an adjunct biomarker for distin-
guishing HCC from CC. 
Acknowledgments
This  work  was  supported  by  the  Thailand
Research Fund (Grant no. MRG4980138) and the
Centre for Research and Development of Medical
Diagnostic Laboratories, Faculty of Associated Med-
ical Sciences, Khon Kaen University, Thailand. We
would like to greatly thank the Liver Fluke and
Cholangiocarcinoma Research Center, Khon Kaen
University, for all samples and clinical data.
References
1. Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum
alpha-fetoprotein for diagnosis of hepatocellular carcino-
ma in patients with chronic liver disease: influence of
HBsAg and anti-HCV status. J Hepatol 2001; 34: 570-5.
2. Bamrungphon W, Prempracha N, Bunchu N, et al. A new
mucin antibody/enzyme-linked lectin-sandwich assay of
serum MUC5AC mucin for the diagnosis of cholangiocar-
cinoma. Cancer Lett 2007; 247: 301-8.
3. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA.
ADAM 12 cleaves extracellular matrix proteins and cor-
relates with cancer status and stage. J Biol Chem 2004;
279: 51323-30.
4. Frohlich C, Albrechtsen R, Dyrskjot L, Rudkjaer L, Orntoft
TF, Wewer UM. Molecular profiling of ADAM12 in human
bladder cancer. Clin Cancer Res 2006; 12: 735-8.
5. Rocks N, Paulissen G, Quesada Calvo F, et al. Expression
of  a disintegrin  and  metalloprotease  (ADAM  and
ADAMTS) enzymes in human non-small-cell lung carci-
nomas (NSCLC). Br J Cancer 2006; 94: 724-30.
6. Le Pabic H, Bonnier D, Wewer UM, et al. ADAM12 in
human liver cancers. TGF-beta-regulated expression in
stellate cells is associated with matrix remodeling. Hepa-
tology 2003; 37: 1056-66.
7. Schwettmann L, Wehmeier M, Jokovic D, et al. J Hepatol
2008; 49: 243-50.
8. Schlondorff J, Blobel CP. Metalloprotease-disintegrins:
modular proteins capable of promoting cell-cell interac-
tions and triggering signals by protein-ectodomain shed-
ding. J Cell Sci 1999; 112: 3603-17.
9. Black RA, White JM. ADAMs: focus on the protease
domain. Curr Opin Cell Biol 1998; 10: 654-9.
10. Uawonggul N, Chaveerach A, Thammasirirak S, Arkar-
avichien T, Chuachan C, Daduang S. Screening of plants
acting against Heterometrus laoticus scorpion venom
activity on fibroblast cell lysis. J Ethnopharmacol 2006;
103: 201-7.
11. Kłysik AB, Kik JN, Hrabec Z, Goś R, Hrabec E. Intraocular
matrix metalloproteinase 2 and 9 in patients with dia-
betes mellitus with and without diabetic retinopathy. Arch
Med Sci 2010; 6: 375-81.